Allogeneic hematopoietic cell transplantation for older patients with Philadelphia-positive acute lymphoblastic leukemia. A study by the Acute Leukemia Working Party of the EBMT.

Giebel, Sebastian; Labopin, Myriam; Swoboda, Ryszard; Blaise, Didier; Yakoub-Agha, Ibrahim; Nguyen, Stephanie; Wagner-Drouet, Eva Maria; Castilla-Llorente, Cristina; Kottaridis, Panagiotis; Schroeder, Thomas; Fanin, Renato; Passweg, Jakob; Versluis, Jurjen; Crawley, Charles; Gabellier, Ludovic; Mielke, Stephan; Poire, Xavier; Nur, Erfan; Vaz, Carlos Pinho; Eder, Matthias

doi:10.1038/s41409-025-02667-2

Allogeneic hematopoietic cell transplantation for older patients with Philadelphia-positive acute lymphoblastic leukemia. A study by the Acute Leukemia Working Party of the EBMT.

Giebel, Sebastian

;

Labopin, Myriam

;

Swoboda, Ryszard

;

Blaise, Didier

;

Ciceri, Fabio

;et.al.

(2025) Bone Marrow Transplantation — Vol. 60, n° 10, p. 1325-1332 (2025)

Files

2025_Giebel_Bone_Marrow_Transplant_AB.pdf

Open Access
Adobe PDF
298.9 KB

Download

Details

Authors

Giebel, Sebastian
Author
Labopin, Myriam
Author
Swoboda, Ryszard
Author
Blaise, Didier
Author
Poire, XavierUCLouvain
Author
Ciceri, Fabio
Author

Abstract

The role of allogeneic hematopoietic cell transplantation (allo-HCT) in older patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) is not well established. In this retrospective analysis we evaluated outcomes of 566 patients with median age of 60 (range 55-76) years treated in first complete remission with allo-HCT from either a matched sibling (n = 138), unrelated (n = 343) or haploidentical (n = 85) donor between the years 2016 and 2022. The probability of overall survival (OS) and leukemia-free survival (LFS) at 2 years was 71% and 59.5%, respectively. The incidence of relapse, and non-relapse mortality (NRM) was 18% and 22.5%, respectively. The rate of graft-versus-host disease (GVHD)-free, relapse-free survival was 50%. In a multivariate model, the use of total body irradiation (TBI) was the only factor affecting outcomes, being associated with reduced risk of NRM (hazard ratio, [HR] = 0.46, p = 0.004), improved LFS (HR = 0.53, p < 0.001) and OS (HR = 0.47, p < 0.001) as well as increased risk of chronic GVHD (HR = 1.68, p = 0.009) and extensive chronic GVHD (HR = 1.84, p = 0.04). We conclude that in the last few years, outcomes of allo-HCT for patients with Ph+ ALL aged ≥55 years are encouraging. TBI-based reduced intensity conditioning appears preferable in this patient population. Our data can serve as a reference for future prospective trials.

Affiliations

Citations

APA
Chicago
FWB

Giebel, S., Labopin, M., Swoboda, R., Blaise, D., Yakoub-Agha, I., Nguyen, S., Wagner-Drouet, E. M., Castilla-Llorente, C., Kottaridis, P., Schroeder, T., Fanin, R., Passweg, J., Versluis, J., Crawley, C., Gabellier, L., Mielke, S., Poire, X., Nur, E., Vaz, C. P., et al. (2025). Allogeneic hematopoietic cell transplantation for older patients with Philadelphia-positive acute lymphoblastic leukemia. A study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplantation, 60(10), 1325-1332. https://doi.org/10.1038/s41409-025-02667-2 (Original work published 2025)